-
公开(公告)号：US20180289794A1
公开(公告)日：2018-10-11
申请号：US15795678
申请日：2017-10-27
Applicant: Variation Biotechnologies Inc.
Inventor： David E. Anderson , Anne-Catherine Fluckiger
Abstract: The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.
-
公开(公告)号：US11248026B2
公开(公告)日：2022-02-15
申请号：US15683355
申请日：2017-08-22
Applicant: Variation Biotechnologies Inc. , Sorbonne Université
IPC: A61K39/12 , A61P31/22 , C07K14/005 , A61K39/245 , A61K39/00
Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US09777043B2
公开(公告)日：2017-10-03
申请号：US14357423
申请日：2012-11-09
Applicant: Variation Biotechnologies, Inc.
Inventor： David E. Anderson , Anne-Catherine Fluckiger
IPC: C07K14/00 , C07K14/005 , A61K39/245 , A61K39/00
CPC classification number: C07K14/005 , A61K39/245 , A61K2039/5258 , A61K2039/70 , C07K2319/00 , C07K2319/03 , C12N2710/16134 , C12N2740/13023 , C12N2760/20234
Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US11167032B2
公开(公告)日：2021-11-09
申请号：US15956099
申请日：2018-04-18
Applicant: Variation Biotechnologies Inc.
Inventor： Marc J. Kirchmeier , David E. Anderson
IPC: A61K39/12 , A61K47/14 , A61K39/395 , C07K16/32 , A61K39/00 , A61K39/165 , A61K39/20 , A61K39/295 , A61K47/24 , A61K47/28 , C12N7/00 , A61K9/127
Abstract: The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).
-
公开(公告)号：US10161010B2
公开(公告)日：2018-12-25
申请号：US15991044
申请日：2018-05-29
Applicant: Variation Biotechnologies Inc.
Inventor： David E. Anderson , Jasminka Bozic , Barthelemy Ontsouka
Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.
-
Patent Agency Ranking
公开(公告)号：US20180274044A1
公开(公告)日：2018-09-27
申请号：US15991044
申请日：2018-05-29
Applicant: Variation Biotechnologies Inc.
Inventor： David E. Anderson , Jasminka Bozic , Barthelemy Ontsouka
CPC classification number: C12Q1/70 , A61K39/12 , A61K2039/5258 , A61K2039/55505 , A61K2039/70 , C12N2710/16134 , G01N33/5044 , G01N33/6854 , G01N2333/045 , G01N2469/20
Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.
-
公开(公告)号：US20180256723A1
公开(公告)日：2018-09-13
申请号：US15810575
申请日：2017-11-13
Applicant: Variation Biotechnologies Inc.
Inventor： David E. Anderson
CPC classification number: A61K47/28 , A61K39/12 , A61K39/205 , A61K39/39 , A61K47/14 , A61K47/24 , A61K2039/55555 , A61K2039/55566 , C12N7/00 , C12N2760/20134 , C12N2760/20171 , Y02A50/466
Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments, the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the antigen is taken from a licensed vaccine and the administered dose of antigen is less than the standard human dose for the licensed vaccine.
-
公开(公告)号：US10006096B2
公开(公告)日：2018-06-26
申请号：US14387870
申请日：2013-03-27
Applicant: VARIATION BIOTECHNOLOGIES, INC.
Inventor： David E. Anderson , Jasminka Bozic , Barthelemy Ontsouka
CPC classification number: C12Q1/70 , A61K39/12 , A61K2039/5258 , A61K2039/55505 , A61K2039/70 , C12N2710/16134 , G01N33/5044 , G01N33/6854 , G01N2333/045 , G01N2469/20
Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.
-
公开(公告)号：US20140356399A1
公开(公告)日：2014-12-04
申请号：US14371935
申请日：2013-01-11
Applicant: Variation Biotechnologies, Inc.
Inventor： David E. Anderson
IPC: A61K47/28 , C12N7/00 , A61K47/24 , A61K39/205 , A61K47/14
CPC classification number: A61K47/28 , A61K39/12 , A61K39/205 , A61K39/39 , A61K47/14 , A61K47/24 , A61K2039/55555 , A61K2039/55566 , C12N7/00 , C12N2760/20134 , C12N2760/20171 , Y02A50/466
Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the antigen is taken from a licensed vaccine and the administered dose of antigen is less than the standard human dose for the licensed vaccine.
Abstract translation: 本公开提供了可用于治疗病毒感染的组合物和方法。 如本文所述，组合物和方法基于包括与非离子表面活性剂囊泡（NISV）组合的灭活病毒的免疫原性组合物的开发。 在某些实施方案中，组合物中存在的至少一部分抗原与NISV物理相关。 在某些实施方案中，将组合物冻干并随后在储存一段时间后再水化。 在某些实施方案中，与缺乏NISV的其它等同组合物相比，再水化组合物表现出更大的效力。 在某些实施方案中，冻干组合物在再水化之前储存在超过8℃的温度下。 在某些实施方案中，与缺乏NISV的其它等同组合物相比，再水合组合物显示出更大的效力，并且在再水合之前也在超过8℃的温度下储存。 在某些实施方案中，抗原是从经许可的疫苗获得的，并且所给予的抗原剂量小于许可疫苗的标准人剂量。
-
公开(公告)号：US20230272013A1
公开(公告)日：2023-08-31
申请号：US17670052
申请日：2022-02-11
Applicant: Variation Biotechnologies Inc.
Inventor： David E. Anderson , Anne-Catherine Fluckiger
IPC: C07K14/005 , A61K39/245
CPC classification number: C07K14/005 , A61K39/245 , A61K2039/70
Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.017 seconds)
